Project Grant HT94252410949
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$336K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
This $835,531 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund a research project at The Johns Hopkins University to develop a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The project aims to transform healthcare for military service members and the broader...
This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...
This federal Project Grant award of $610,059.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by The Johns Hopkins University to investigate "The Aging Microenvironment as a Driver of Pancreatic Cancer Metastasis." The award has a performance period from July 1, 2025 to June 30, 2028 and aims to transform healthcare for military service members, veterans, and the general public through innovative biomedical...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $388,194 to The Johns Hopkins University to conduct research on "The Aging Microenvironment as a Driver of Pancreatic Cancer Metastasis." The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical solutions for critical health challenges. The 3-year project, running from...
This federal Project Grant award of $360,413.00, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University focused on early hepatic dissemination of pancreatic cancer. The research aims to evaluate the efficacy of systemic chemotherapy-enhanced alpha-particle radiotherapy as a treatment approach. The award has a performance period from November 1, 2024 to October 31, 2027. As a leading academic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Johns Hopkins University to develop a mutant KRAS-targeted vaccine for the interception of pancreatic cancer development. The total award amount is $659,090 over the project period from September 1, 2024 to August 31, 2029. The key objectives are to evaluate the safety and immunogenicity of the mutant KRAS vaccine in individuals with genetic predisposition to pancreatic...
This $1,473,750 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research study on "The Immunomodulatory Impact of Chemotherapy When Combined with PD-1 Blockade in Resectable Lung Cancer." The 3-year grant, running from September 1, 2024 to August 31, 2027, aims to investigate innovative immunological interventions for treating lung cancer in military service...
The Johns Hopkins University will receive $620,588 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research to develop a 3D multiscale analysis of malignant progression in human pancreatic cancer. Through September 2025, researchers will investigate medical solutions for pancreatic cancer at the cellular and tissue levels to transform understanding and treatment of this...
This federal Project Grant award of $589,838.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Johns Hopkins University. The grant supports research to optimize an active mutant KRAS peptide vaccine for the treatment of colorectal cancer (CRC), which is the second leading cause of cancer-related mortality in the U.S. The research aims to develop improved methods for cancer treatment and increase cure rates for CRC patients....
The U.S. Defense Health Agency awarded a $776,831 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University to conduct research on P2 purinergic receptors in pancreatic ductal adenocarcinoma as potential therapeutic targets. The grant, which runs from August 1, 2025 to July 31, 2028, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. As a leading...